沙利度胺联合方案治疗老年多发性骨髓瘤临床对照研究

目的评价沙利度胺联合方案治疗老年多发性骨髓瘤（MM）治疗效果及应用价值。方法56例老年MM患者随机分为MPT组30例和MP组26例，分别采用沙利度胺＋马法兰＋泼尼松（MPT）方案及马法兰＋泼尼松（MP）方案治疗，评价治疗效果、无进展生存期（PFS）及PFS生存率。结果M阴组和MP组的ORR分别为83．33％和57．69％，其中CR率分别为16．67％和3．85％，差异有统计学意义（P〈0．05）。MTT组血红蛋白、白蛋白显著高于MP组，骨髓浆细胞百分比显著低于MP组（P〈0．05），均无严重不良反应。M阳组PFS和2年PFS生存率均显著优于MP组（P〈0．01）。结论沙利度胺联合MP方案治疗老年MM疗效确切、安全性好，能有效提高患者生存质量，延长PFS，提高PFS生存率。

Clinical study of thalidomide combined chemotherapy protocol for elderly patients with multiple myeloma

Objective To investigate the efficacy and value of thalidomide combined chemotherapy protocol for elderly patients with multiple myeloma(MM).Methods All 56 cases of MM were randomly divided into MPT group(30 cases) and MP group(26 cases),and respectively treated by thalidomide plus melphalan plus prednisone(MPT) protocol and melphalan plus prednisone(MP) protocol.Assessed the efficacy,progression-free survival(PFS) and PFS rate.Results ORR of two groups were 83.33% and 57.69%,and CR were 16.67% and 3.85%,the difference had statistically significant(P < 0.05).The Hb and albumin of MPT group were statistically higher than MP group,the percentage of bone marrow plasma cells was statistically lower than MP group(P < 0.05).The PFS and 2years PFS rate of MPT group was higher than MP group(P < 0.01).Conclusion Thalidomide plus MP treatment for elderly patients with MM could achieve higher response rate,good tolerance,improve the life quality,prolong the PFS and higher PFS rate.